Related Experiment Videos
Antifungal agents and immunomodulators in systemic mycoses
1Medical Mycology Division, Central Drug Research Institute, Lucknow. root@cscdri.ren.nic.in
The Indian Journal of Chest Diseases & Allied Sciences
|December 16, 2004
Summary
The increasing threat of fungal infections drives the development of new antifungal drugs. This review covers key antifungal classes and research advancements, highlighting a rapidly growing market for these essential medicines.
Area of Science:
- Medical Mycology
- Pharmacology
Background:
- Rising incidence of fungal infections and opportunistic fungal pathogens necessitates new treatments.
- Significant progress in developing novel antifungal agents for systemic mycoses over recent decades.
Purpose of the Study:
- To provide an updated review of available information on various antifungal agents.
- To highlight ongoing and completed research in antifungals at the Central Drug Research Institute (CDRI).
Main Methods:
- Review of existing literature on antifungal agents.
- Discussion of drug classes including polyenes, imidazoles, triazoles, flucytosine, allylamines, echinocandins, nikkomycins, sordarins, and immunomodulators.
Main Results:
- Antifungals constitute over 6% of the global anti-infective market.
- The antifungal market shows a 20% annual expansion, projected to exceed $15 billion USD within a decade.
Conclusions:
- Continued research and development are crucial for addressing the growing challenge of fungal infections.
- The expanding market indicates a significant and increasing demand for effective antifungal therapies.